5. USFDA approves Johnson & Johnson’s one dose COVID -19 vaccine stating it to be 85 % effective against the virus : The United States has once been plaques by COVID -19 since the beginning, and over 510,000 people have succumbed to this illness to date. Mutations in this virus have also added up to […]
Sun Pharma’s appeal regarding Taclantis– its breast cancer drug application has been ruled out by USFDA Sun Pharma Advanced Research Company ( SPARC ) had recently submitted an NDA[1] for Taclantis to the USFDA[2]. Taclantis is a product that is currently under development for the treatment of breast cancer. This appeal has, however, been declined
Sun Pharma launches generic Brevipil tablet following patent expiry of the innovator product. (1) Sun Pharmaceuticals have recently launched an anti–epileptic drug called Brevipil in the market. The company did this launch on 22 February 2021, a day after the expiry of the innovator drug’s patent. The innovator drug for this generic version is called Brivaracetam.
Lupin and Aurobindo Pharma initiates nationwide recall Pharma News – 20 February: The latest enforcement report of the USFDA[1] has led to the recall of certain medications by two major pharma companies. The companies involved are Lupin and Aurobindo Pharma. Baltimore – based unit of Lupin Pharmaceuticals Inc. has been actively recalling an antiviral medication.
BioNTech ramps up production of its COVID – 19 vaccine to meet global demands : Pharma News February 2021: The German biotechnology firm has recently announced that it would produce over two billion doses of its COVID – 19 vaccines in 2021. The company added that it plans to scale up its manufacturing capacities to
Ignorance and credulous hope make the market for most proprietary remedies. Samuel Hopkins Adams -US journalist and author Lupin initiates Class II recall of Mibelas 24 Fe pouches in theUS market: Pharma News – 23 Aug: Drug firm Lupin is voluntarily recalling around 5,60,922 pouches of Mibelas 24 Fe in the US [1]. The nationwide
Atrimed Pharma receives ICMR’s approval for the clinical trials its plant-based Covid-19 drugs Pharma News – 16 August: Atrimed Pharma is a Bengaluru-based pharmaceutical company. This drug firm mainly focuses on the development of phytopharmaceuticals and plant-based medications. It had recently received the ICMR’s[1] approval for conducting clinical trials on three of its phytomolecules. The
Cipla’s Goa plant begins production of Remdesivir to meet the increased demand: Pharma News – 13 August: The surge in the number of Covid-19 cases has increased the demand for Remdesivir. As current production capacity remains insufficient to meet this growing demand, pharmaceutical companies are ramping up their production. In accordance with this scenario, pharma
Glenmark plans to launch Fabiflu 400 mg for the treatment of Covid-19: Pharma News – 9 August: Glenmark Pharmaceuticals announced the launch of Fabiflu 400 mg in the Indian market (On 6 August 2020). Fabiflu is an oral antiviral drug that was initially launched in the 200 mg strength. It is used for the treatment
Lupin pharmaceuticals recall Cefdinir for oral suspension from the US market : Pharma News – 6 August: Lupin Pharmaceuticals Inc., based in Baltimore, USA[1] had initiated a countrywide recall of its antibiotic on 2 July 2020. This generic antibiotic is called Cefdinir for oral suspension USP, 250 mg /5mL. It is packaged in 60 mL
